otamixaban otamixaban otamixaban (inn) is an experimental injectable anticoagulant direct factor xa inhibitor that was investigated for the treatment for acute coronary syndrome. in 2013, sanofi announced that it had ended development of the drug candidate after poor performance in a phase iii clinical trial. otamixabanclinical dataatc codenoneidentifiers iupac name methyl (2r,3r)-2--3-butanoate cas number193153-04-7 npubchem cid5496659chemspider4593439 yuniis173red00lchemblchembl46618 ycomptox dashboard (epa)dtxsid40172917 chemical and physical dataformulac25h26n4o4molar mass446.507 g·mol−13d model (jsmol)interactive image smiles o=c(oc)(cc1cc(c(=)n)ccc1)(nc(=o)c3ccc(c2cc()cc2)cc3)c inchi inchi=1s/c25h26n4o4/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19/h3-14,16,22h,15h2,1-2h3,(h3,26,27)(h,28,30)/t16-,22-/m1/s1 ykey:pfgvnlzdwrzpjw-opamfihvsa-n y ny (what is this?) (verify)